HI-Bio
Latest round
- Series B
Last raised
- Sep 2023
Total raised
- $108M
Investors
- 6
About HI-Bio
Based in California, US, and founded in 2021, Human Immunology Biosciences, Inc. trading as HI-Bio, operates as a biotechnological company developing precision medicines to treat people suffering from autoimmune and inflammatory diseases. Human Immunology Biosciences, Inc. develops a slate of precision medicines targeting cellular drivers of this dysfunction, including its lead program, the plasma depletion agent felzartamab. It provides a precision immunology toolkit consisting of four pillars human genetics, human immunophenotyping, data sciences, and therapeutic engineering that helps translate insights that emerge from ongoing research and development efforts.
Who invested in HI-Bio
6 investors across 3 rounds
See all investors in HI-Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about HI-Bio
Who invested in HI-Bio?
HI-Bio has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has HI-Bio raised?
HI-Bio has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did HI-Bio last raise money?
HI-Bio's most recent round on record is a Series B, in Sep 2023.
What does HI-Bio do?
Based in California, US, and founded in 2021, Human Immunology Biosciences, Inc.
Where is HI-Bio headquartered?
HI-Bio is headquartered in South San Francisco, US.
Which VCs invest in companies like HI-Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at HI-Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like HI-Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.